Supernus Pharma (SUPN) Misses Q1 EPS by 13c, Revenues Beat; Offers FY21 Revenues Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Supernus Announces First Quarter 2021 Financial Results
May 5, 2021 4:01 PM EDTFirst quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020Qelbree approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021Qelbree sNDA submission for adult ADHD anticipated in the third quarter of 2021SPN-830 (apomorphine infusion pump) NDA resubmission anticipated in the second half of 2021SPN-820 (mTORC1) has advanced towards a Phase II clinical program in treatment-resistant depression following successful completion of MAD study
ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Supernus... More
